Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.

Geahča maid

• Once- versus twice-daily abacavir and lamivudine in African children: the randomised controlled ARROW Trial
  Dahkki: Musiime, V, et al.
  Almmustuhtton: (2016)
• Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13).
  Dahkki: Bergshoeff, A, et al.
  Almmustuhtton: (2005)
• Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children.
  Dahkki: Fillekes, Q, et al.
  Almmustuhtton: (2014)
• Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children.
  Dahkki: LePrevost, M, et al.
  Almmustuhtton: (2006)
• Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children.
  Dahkki: Green, H, et al.
  Almmustuhtton: (2007)